A crucial role of angiotensin converting enzyme 2 (ACE2) in SARS coronavirus–induced lung injury

Kuba, Keiji, Imai, Yumiko, Rao, Shuan, Gao, Hong, Guo, Feng, Guan, Bin, Huan, Yi, Yang, Peng +16 more·2005·Nature Medicine
DOI 10.1038/nm1267

Cited by (1,008)

Items 301–400 of 1,008

  1. The Role of Angiotensin Converting Enzyme 2 in Modulating Gut Microbiota, Intestinal Inflammation, and Coronavirus Infection
    Josef Martin Penninger, Maria B. Grant, Joseph J.�Y. Sung · 2020 · Gastroenterology
  2. Pathogenesis of Multiple Organ Injury in COVID-19 and Potential Therapeutic Strategies
    Miquéias Lopes‐Pacheco, Pedro Leme Silva, Fernanda Ferreira Cruz, Denise Battaglini, Chiara Robba, Paolo P. Pelosi, Marcelo Marcos Morales, Celso Caruso Neves, Patrícia R. M. Rocco · 2021 · Frontiers in Physiology
  3. Comparing machine learning algorithms for predicting ICU admission and mortality in COVID-19
    Sonu Subudhi, Ashish Verma, Ankit Bharat Patel, Corey Hardin, Melin Janardan Khandekar, Hang Lee, Dustin S. McEvoy, Triantafyllos Stylianopoulos, Lance L. Munn, Sayon Dutta et al. · 2021 · npj Digital Medicine
  4. ESC guidance for the diagnosis and management of cardiovascular disease during the COVID-19 pandemic: part 2—care pathways, treatment, and follow-up
    The Task Force for the management of COVID-19 of the European Society of Cardiology, Colin Baigent, Stephan Windecker, Daniele Andreini, Elena Arbelo, Emanuele Barbato, Antonio Luca Bartorelli, Andreas Baumbach, Elijah Raphael Behr, Sérgio Luis Berti et al. · 2021 · European Heart Journal
  5. Relation of Statin Use Prior to Admission to Severity and Recovery Among COVID-19 Inpatients
    Lori B. Daniels, Amy M. Sitapati, Jing Zhang, Jingjing Zou, Quan M. Bui, Junting Ren, Chris Longhurst, Michael H. Criqui, Karen S. Messer · 2020 · The American Journal of Cardiology
  6. Angiotensin-Converting Enzyme 2 and Antihypertensives (Angiotensin Receptor Blockers and Angiotensin-Converting Enzyme Inhibitors) in Coronavirus Disease 2019
    Fabián Sanchis‐Gomar, Carl J. Lavie, Carme Pérez-Quilis, Brandon Michael Henry, Giuseppe Lippi · 2020 · Mayo Clinic Proceedings
  7. Recent advances involving the renin–angiotensin system
    Steven D. Crowley, Thomas M. Coffman · 2012 · Experimental Cell Research
  8. ACE2: A New Target for Cardiovascular Disease Therapeutics
    Mohan K. Raizada, Anderson Jose Ferreira · 2007 · Journal of Cardiovascular Pharmacology
  9. Crosstalk between the renin–angiotensin, complement and kallikrein–kinin systems in inflammation
    Bekassy, Zivile, Lopatko Fagerström, Ingrid, Bader, Michael, Karpman, Diana · 2022 · Nature reviews. Immunology
  10. Surface vimentin is critical for the cell entry of SARS-CoV
    Yvonne Ting-Chun Yu, Ssu-Chia Chien, I-Yin Chen, Chia-Tsen Lai, Yeou‐Guang Tsay, Shin C. Chang, Ming‐Fu Chang · 2016 · Journal of Biomedical Science
  11. The Effects of ARBs, ACEis, and Statins on Clinical Outcomes of COVID-19 Infection Among Nursing Home Residents
    Anton De Spiegeleer, Antoon Bronselaer, James Teo, Geert Byttebier, Guy De Tré, Luc Belmans, Richard Dobson, Evelien Wynendaele, Christophe Van de Wiele, Filip Vandaele et al. · 2020 · Journal of the American Medical Directors Association
  12. The pivotal role of TMPRSS2 in coronavirus disease 2019 and prostate cancer
    Veronica Mollica, Alessandro Rizzo, Francesco Massari · 2020 · Future Oncology
  13. Colorimetric and electrochemical detection of SARS-CoV-2 spike antigen with a gold nanoparticle-based biosensor
    Erman Karakuş, Eda Erdemir, Nisa Demirbilek, Lokman Liv · 2021 · Analytica Chimica Acta
  14. Cellular and Molecular Pathways of COVID-19 and Potential Points of Therapeutic Intervention
    John P. Hussman · 2020 · Frontiers in Pharmacology
  15. The NLRP3 inflammasome and COVID-19: Activation, pathogenesis and therapeutic strategies
    Ni Zhao, Bin Di, Lili Xu · 2021 · Cytokine & Growth Factor Reviews
  16. Modulation of angiotensin II signaling in the prevention of fibrosis
    Amanda M. Murphy, Alison L. Wong, Michael Bezuhly · 2015 · Fibrogenesis & Tissue Repair
  17. Hyperinflammatory Response in COVID-19: A Systematic Review
    Marcos Jessé Abrahão Silva, Layana Rufino Ribeiro, Maria Isabel Montoril Gouveia, Beatriz dos Reis Marcelino, Carolynne Silva dos Santos, Karla Valéria Batista Lima, Luana Nepomuceno Gondim Costa Lima · 2023 · Viruses
  18. The SARS-CoV-2 Exerts a Distinctive Strategy for Interacting with the ACE2 Human Receptor
    Esther S. Brielle, Dina Schneidman‐Duhovny, Michal Linial B · 2020 · Viruses
  19. The mechanism and treatment of gastrointestinal symptoms in patients with COVID-19
    Qing Ye, Bili Wang, Ting Zhang, Jian Xu, Shiqiang Shang · 2020 · American Journal of Physiology-Gastrointestinal and Liver Physiology
  20. Mechanisms and Clinical Consequences of Acute Lung Injury
    Vito Fanelli, Vito Marco Ranieri · 2015 · Annals of the American Thoracic Society
  21. Can Zn Be a Critical Element in COVID-19 Treatment?
    Mohammad Tariqur Rahman, Syed Zahir Idid Syed Osman Idid · 2020 · Biological Trace Element Research
  22. How does the COVID-19 cause seizure and epilepsy in patients? The potential mechanisms
    Farnaz Nikbakht, Ali Mohammadkhanizadeh, Ekram Mohammadi · 2020 · Multiple Sclerosis and Related Disorders
  23. Pandemic Influenza: A Potential Role for Statins in Treatment and Prophylaxis
    David S. Fedson · 2006 · Clinical Infectious Diseases
  24. Geranium and Lemon Essential Oils and Their Active Compounds Downregulate Angiotensin-Converting Enzyme 2 (ACE2), a SARS-CoV-2 Spike Receptor-Binding Domain, in Epithelial Cells
    K. J. Senthil Kumar, M. Gokila Vani, Chung-Hsuan Wang, Chia‐Chi Chen, Yu-Chien Chen, LU Li-ping, Ching-Hsiang Huang, Chien-Sing Lai, Sheng‐Yang Wang · 2020 · Plants
  25. Putative roles of vitamin D in modulating immune response and immunopathology associated with COVID-19
    Raman Kumar, Himani Rathi, Afrozul Haq, Sunil J. Wimalawansa, Alpana Sharma · 2020 · Virus Research
  26. TMEM106B is a receptor mediating ACE2-independent SARS-CoV-2 cell entry
    Jim Baggen, Maarten Jacquemyn, Leentje Persoons, Els Vanstreels, Valerie E. Pye, Antoni G. Wrobel, Valeria Calvaresi, Stephen R. Martin, Chloë Roustan, Nora Cronin et al. · 2023 · Cell
  27. Upregulation of hepatic angiotensin-converting enzyme 2 (ACE2) and angiotensin-(1–7) levels in experimental biliary fibrosis
    Chandana B. Herath, Fiona J. Warner, John Samuel Lubel, Rachael G. Dean, Zhiyuan Jia, Rebecca A. Lew, A. Ian Smith, Louise M. Burrell, Peter Angus · 2007 · Journal of Hepatology
  28. Clinical Implications of SARS-CoV-2 Interaction With Renin Angiotensin System
    Agnieszka Brojakowska, Jagat Narula, Rony Y. Shimony, Jeffrey A. Bander · 2020 · Journal of the American College of Cardiology
  29. Understanding the renin–angiotensin–aldosterone–SARS-CoV axis: a comprehensive review
    Nicholas E. Ingraham, Abdo Barakat, Ronald A. Reilkoff, Tamara L Bezdicek, Timothy W. Schacker, Jeffrey G. Chipman, Christopher James Tignanelli, Michael A. Puskarich · 2020 · European Respiratory Journal
  30. Inhaled corticosteroids downregulate the SARS-CoV-2 receptor ACE2 in COPD through suppression of type I interferon
    Lydia Finney, Nicholas Glanville, Hugo Andres Farne, Julia Aniscenko, Peter S Fenwick, Samuel V. Kemp, Maria-Belen Trujillo-Torralbo, Su-Ling Loo, Maria Adelaide Calderazzo, Jadwiga Anna Wedzicha et al. · 2020 · Journal of Allergy and Clinical Immunology
  31. Lung epithelium as a sentinel and effector system in pneumonia – molecular mechanisms of pathogen recognition and signal transduction
    Stefan Hippenstiel, Bastian Opitz, Bernd Schmeck, Norbert Suttorp · 2006 · Respiratory Research
  32. Three key proteases – angiotensin-I-converting enzyme (ACE), ACE2 and renin – within and beyond the renin-angiotensin system
    Cuie Guang, Robert Dixon Phillips, Bo Jiang, Franco Milani · 2012 · Archives of cardiovascular diseases
  33. The ACE-2 in COVID-19: Foe or Friend?
    Rinkoo Dalan, Stefan Richard Bornstein, Ali El‐Armouche, Roman Nikolaevich Rodionov, Alexander Georgievich Markov, Ben Wielockx, Felix Beuschlein, Bernhard Otto Boehm · 2020 · Hormone and Metabolic Research
  34. Address for correspondence
    Marco Rosati · 2011 · Studies in bilingualism
  35. Unravelling lead antiviral phytochemicals for the inhibition of SARS-CoV-2 Mpro enzyme through in silico approach
    Arun Bahadur Gurung, Mohammad Ajmal Ali, Joongku Lee, Mohammad Abul Farah, Khalid Mashay Al‐Anazi · 2020 · Life Sciences
  36. ACE2 expression and sex disparity in COVID-19
    Maria Cristina Gagliardi, Paolo Tieri, Elena Ortona, Anna Ruggieri · 2020 · Cell Death Discovery
  37. Potential use of polyphenols in the battle against COVID-19
    Ines L. Paraiso, Johana S. Revel, Jan Frederik Stevens · 2020 · Current Opinion in Food Science
  38. Angiotensin II plasma levels are linked to disease severity and predict fatal outcomes in H7N9-infected patients
    Fengming Huang, Jing Guo, Zhen Zou, Jun Liu, Bin Cao, Shuyang Zhang, Hui Li, Wei Wang, Miaomiao Sheng, Song Liu et al. · 2014 · Nature Communications
  39. Redefining Cardiac Biomarkers in Predicting Mortality of Inpatients With COVID-19
    Juan‐Juan Qin, Xu Cheng, Feng Zhou, Fang Lei, Gauri Akolkar, Jingjing Cai, Xiao-Jing Zhang, Alice Blet, Jing Xie, Peng Zhang et al. · 2020 · Hypertension
  40. Comprehensive characterization of N- and O- glycosylation of SARS-CoV-2 human receptor angiotensin converting enzyme 2
    Asif Shajahan, Stephanie A. Archer‐Hartmann, Nitin T. Supekar, Anne S. Gleinich, Christian Heiß, Parastoo Azadi · 2020 · Glycobiology
  41. Cardiovascular complications of COVID-19
    Farnaz Farshidfar, Navid Koleini, Hossein Ardehali · 2021 · JCI Insight
  42. Fermented Soy Products and Their Potential Health Benefits: A Review
    Fernanda Guilherme do Prado, Maria Giovana Binder Pagnoncelli, Gilberto Vinícius de Melo Pereira, Susan Grace Karp, Carlos Ricardo Soccol · 2022 · Microorganisms
  43. Identification of pulmonary Oct-4 + stem/progenitor cells and demonstration of their susceptibility to SARS coronavirus (SARS-CoV) infection in vitro
    Thai‐Yen Ling, Ming‐Der Kuo, Chung-Leung Li, Alice Lin-Tsing Yu, Yen‐Hua Huang, Tsai‐Jung Wu, You-Chin Lin, Shu-Hwa Chen, John Yu · 2006 · Proceedings of the National Academy of Sciences
  44. Lungs as target of COVID-19 infection: Protective common molecular mechanisms of vitamin D and melatonin as a new potential synergistic treatment
    Virna Margarita Martín Giménez, Felipe Inserra, Carlos Daniel Tajer, Javier A. Mariani, León Ferder, Russel Joseph Reiter, Walter A. Manucha · 2020 · Life Sciences
  45. Traditional Chinese medicine for pulmonary fibrosis therapy: Progress and future prospects
    Liucheng Li, Lian‐Di Kan · 2016 · Journal of Ethnopharmacology
  46. Virology, pathogenesis, diagnosis and in-line treatment of COVID-19
    Pavan Kumar Samudrala, Pramod Kumar, Kamlesh Choudhary, Nagender Thakur, Gaurav Suresh Wadekar, Richa A. Dayaramani, Mukta Agrawal, Amit Alexander · 2020 · European Journal of Pharmacology
  47. Thrombotic complications of COVID-19
    Avila, Jacob, Long, Brit, Holladay, Dallas, Gottlieb, Michael · 2021 · The American Journal of Emergency Medicine
  48. Potential harmful effects of discontinuing ACE-inhibitors and ARBs in COVID-19 patients
    Gian Paolo Rossi, Viola Sanga, Matthias Barton · 2020 · eLife
  49. Sex Differences in Case Fatality Rate of COVID-19: Insights From a Multinational Registry
    Mohamad Adnan Alkhouli, Aravinda Nanjundappa, Frank Annie, Mark C. Bates, Deepak L. Bhatt · 2020 · Mayo Clinic Proceedings
  50. Curcumin (a constituent of turmeric): New treatment option against COVID‐19
    Fatemeh Babaei, Marjan Nassiri‐Asl, Hossein Hosseinzadeh · 2020 · Food Science & Nutrition
  51. IL-6 Inhibitors in the Treatment of Serious COVID-19: A Promising Therapy?
    Shubham Atal, Zeenat Fatima · 2020 · Pharmaceutical Medicine
  52. The four horsemen of a viral Apocalypse: The pathogenesis of SARS-CoV-2 infection (COVID-19)
    Peré Domingo, Isabel Mur, Virginia Pomar, Hèctor Corominas, Jordi Casademont, Natividad Benito · 2020 · EBioMedicine
  53. Prevention of Pulmonary Hypertension by Angiotensin-Converting Enzyme 2 Gene Transfer
    Yoriko Yamazato, Anderson Jose Ferreira, Kwonho Hong, Srinivas Sriramula, Joseph Francis, Masanobu Yamazato, Lihui Yuan, Chastity Bradford, Vinayak Shenoy, Suk Paul Oh et al. · 2009 · Hypertension
  54. Potential Causes and Consequences of Gastrointestinal Disorders during a SARS-CoV-2 Infection
    François Trottein, Harry Sokol · 2020 · Cell Reports
  55. A comparative overview of COVID-19, MERS and SARS: Review article
    Jie Liu, Wanli Xie, Yanting Wang, Yue Xiong, Shiqiang Chen, Jingjing Han, Qingping Wu · 2020 · International Journal of Surgery
  56. Evidence for treatment with estradiol for women with SARS-CoV-2 infection
    Ute Seeland, Flaminia Coluzzi, Maurizio Simmaco, Cameron Mura, Philip E. Bourne, Max Heiland, Robert Preißner, Saskia Preißner · 2020 · BMC Medicine
  57. Emergence of Novel Coronavirus and COVID-19: whether to stay or die out?
    Asim Biswas, Uttaran Bhattacharjee, Alok Kumar Chakrabarti, Devendra Nath Tewari, Hasina Banu, Shanta Dutta · 2020 · Critical Reviews in Microbiology
  58. Understanding the role of ACE-2 receptor in pathogenesis of COVID-19 disease: a potential approach for therapeutic intervention
    Ekta Shirbhate, Jaiprakash Pandey, Vijay K. Patel, Mehnaz Kamal, Talha Jawaid, Bapi Gorain, Prashant Kesharwani, Harish Rajak · 2021 · Pharmacological Reports
  59. Cytokine storm in COVID-19: from viral infection to immune responses, diagnosis and therapy
    Yi-Zhou Jiang, Limor Rubin, Tangming Peng, Linlin Liu, Xingan Xing, Philip Lazarovici, Wenhua Zheng · 2021 · International Journal of Biological Sciences
  60. Replication-dependent downregulation of cellular angiotensin-converting enzyme 2 protein expression by human coronavirus NL63
    Ronald Dijkman, Maarten F. Jebbink, Martin Deijs, Aleksandra Milewska, Krzysztof Pyrć, Elena Buelow, Anna van der Bijl, Lia van der Hoek · 2012 · Journal of General Virology
  61. Curcumin as a Potential Treatment for COVID-19
    Bruna Amanda da Cruz Rattis, Simone Gusmão Ramos, Mara Rúbia Nunes Celes · 2021 · Frontiers in Pharmacology
  62. COVID-19 and Alzheimer’s disease: how one crisis worsens the other
    Xiaohuan Xia, Yi Wang, Jialin Zheng · 2021 · Translational Neurodegeneration
  63. A brief review of interplay between vitamin D and angiotensin‐converting enzyme 2: Implications for a potential treatment for COVID ‐19
    Aida Malek Mahdavi · 2020 · Reviews in Medical Virology
  64. Does SARS-CoV-2 Bind to Human ACE2 More Strongly Than Does SARS-CoV?
    Hoang Linh Nguyen, Pham Dang Lan, Nguyen Quoc Thai, Daniel Allen Nissley, Edward P. O’Brien, Mai Suan Li · 2020 · The Journal of Physical Chemistry B
  65. Asthma among hospitalized patients with COVID-19 and related outcomes
    Stephanie Lovinsky‐Desir, Deepti Deshpande, Aliva De, Laurie P. Murray, Jeanette A. Stingone, Angela Chan, Neha N Patel, Nooralam Rai, Emily DiMango, Joshua D. Milner et al. · 2020 · Journal of Allergy and Clinical Immunology
  66. An alteration of the dopamine synthetic pathway is possibly involved in the pathophysiology of COVID‐19
    Serge Nataf · 2020 · Journal of Medical Virology
  67. Endocytosis of the receptor-binding domain of SARS-CoV spike protein together with virus receptor ACE2
    Shunxin Wang, Feng Guo, Kangtai Liu, Hongliang Wang, Shuan Rao, Peng Yang, Chengyu Jiang · 2008 · Virus Research
  68. Lessons from SARS: control of acute lung failure by the SARS receptor ACE2
    Keiji Kuba, Yumiko Imai, Shuan Rao, Chengyu Jiang, Josef Martin Penninger · 2006 · Journal of Molecular Medicine
  69. Potential role of ACE2 in coronavirus disease 2019 (COVID-19) prevention and management
    Mengyuan Liu, Ting Wang, Yun Zhou, Yutong Zhao, Yan Zhang, Jianping Li · 2020 · Journal of Translational Internal Medicine
  70. Angiotensin-converting enzyme 2 (ACE2): SARS-CoV-2 receptor and RAS modulator
    Jingwei Bian, Zijian Li · 2020 · Acta Pharmaceutica Sinica B
  71. The SARS-CoV-2 receptor, ACE-2, is expressed on many different cell types: implications for ACE-inhibitor- and angiotensin II receptor blocker-based cardiovascular therapies
    Adriana Albini, Giovanni Di Guardo, Douglas McClain Noonan, Michele Lombardo · 2020 · Internal and Emergency Medicine
  72. SARS-CoV-2 Mediated Endothelial Dysfunction: The Potential Role of Chronic Oxidative Stress
    Ryan P. Chang, Abrar Mamun, Abishai Dominic, Nhat‐Tu Le · 2021 · Frontiers in Physiology
  73. COVID‑19 in Northern Italy: An integrative overview of factors possibly influencing the sharp increase of the outbreak (Review)
    Μαρίνα Γούμενου, Dimosthenis Andreas Sarigiannis, Aristidis Michael Tsatsakis, Ourania Anesti, Anca Oana Docea, Dimitrios Petrakis, Dimitris Tsoukalas, Ronald Neil Kostoff, Valeri Rakitskii, Demetrios A. Spandidos et al. · 2020 · Molecular Medicine Reports
  74. Downregulation of ACE2 induces overstimulation of the renin–angiotensin system in COVID-19: should we block the renin–angiotensin system?
    François Silhol, Gabrielle Sarlon, Jean‐Claude Deharo, Bernard Vaisse · 2020 · Hypertension Research
  75. Pathophysiology and Pathology of Acute Kidney Injury in Patients With COVID-19
    Jia Hwei Ng, Vanesa Bijol, Matthew A. Sparks, Meghan E. Sise, Hassane Izzedine, Kenar D. Jhaveri · 2020 · Advances in Chronic Kidney Disease
  76. ACE2 and COVID-19 and the resulting ARDS
    Xiaoqing Zhang, Shuren Li, Shaoqian Niu · 2020 · Postgraduate Medical Journal
  77. Severe COVID-19 and aging: are monocytes the key?
    Brandt D. Pence · 2020 · GeroScience
  78. CNS implications of COVID-19: a comprehensive review
    Priyanka Nagu, Arun Parashar, Tapan Behl, Vineet Mehta · 2020 · Reviews in the Neurosciences
  79. SARS-CoV-2 and ACE2: The biology and clinical data settling the ARB and ACEI controversy
    Mina K. Chung, Sadashiva S. Karnik, Joshua Saef, Cornelia C. Bergmann, John Barnard, Michael M. Lederman, John C. Tilton, Feixiong Cheng, Clifford V. Harding, James B. Young et al. · 2020 · EBioMedicine
  80. Molecular diversity of coronavirus host cell entry receptors
    Jean K. Millet, Javier A. Jaimes, Gary R. Whittaker · 2020 · FEMS Microbiology Reviews
  81. Sympathetic activation: a potential link between comorbidities and COVID‐19
    Andrea Porzionato, Aron Emmi, Silvia Barbon, Rafael Boscolo-berto A, Carla Stecco, Elena Stocco, Veronica Macchi, Raffaele De · 2020 · FEBS Journal
  82. ACE2 polymorphism and susceptibility for SARS-CoV-2 infection and severity of COVID-19
    Birte Möhlendick, Kristina Schönfelder, Katharina Breuckmann, Carina Elsner, Nina Babel, Paul Balfanz, Edgar Dahl, Michael Dreher, David Fistera, Frank Herbstreit et al. · 2021 · Pharmacogenetics and Genomics
  83. SARS-CoV-2 in immunocompromised individuals
    Susan DeWolf, Justin C. Laracy, Miguel‐Angel Perales, Mini Kamboj, Marcel R.M. van den Brink, Santosha Adipudi Vardhana · 2022 · Immunity
  84. TACE antagonists blocking ACE2 shedding caused by the spike protein of SARS-CoV are candidate antiviral compounds
    Shiori Haga, Noriyo Nagata, Tadashi Okamura, Norio Yamamoto, Tetsutaro Sata, Naoki Yamamoto, Takehiko Sasazuki, Yukihito Ishizaka · 2009 · Antiviral Research
  85. Angiotensin-converting enzyme 2 in acute respiratory distress syndrome
    Yumiko Imai, Keiji Kuba, Josef Martin Penninger · 2007 · Cellular and Molecular Life Sciences
  86. Viral-Induced Enhanced Disease Illness
    Maria K. Smatti, Asmaa A. Al Thani, Hadi Mohamad Yassine · 2018 · Frontiers in Microbiology
  87. Coagulopathy in COVID-19: Manifestations and management
    Simon R. Mucha, Siddharth Pawan Dugar, Keith R. McCrae, Douglas Joseph, John R. Bartholomew, Gretchen L. Sacha, Michael Anthony Militello · 2020 · Cleveland Clinic Journal of Medicine
  88. N-Acetylcysteine: A potential therapeutic agent for SARS-CoV-2
    Francis L. Poe, Joshua Corn · 2020 · Medical Hypotheses
  89. Angiotensin-converting enzyme 2—at the heart of the COVID-19 pandemic
    Gavin Y. Oudit, Kaiming Wang, Anissa Viveiros, Max J. Kellner, Josef Martin Penninger · 2023 · Cell
  90. On Facing the SARS-CoV-2 (COVID-19) with Combination of Nanomaterials and Medicine: Possible Strategies and First Challenges
    Vishnu Sankar Sivasankarapillai, Akhilash Mohanan Pillai, Abbas Rahdar, Parayil Sobha Anumol, Sabya Sachi Das, Athanasios C. Mitrοpoulos, Mahboobeh Heidari Mokarrar, George Z. Kyzas · 2020 · Nanomaterials
  91. Decreased Mortality of COVID-19 With Renin-Angiotensin-Aldosterone System Inhibitors Therapy in Patients With Hypertension
    Xiaoming Guo, Yueli Zhu, Yuan Hong · 2020 · Hypertension
  92. Intestinal Inflammation Modulates the Expression of ACE2 and TMPRSS2 and Potentially Overlaps With the Pathogenesis of SARS-CoV-2–related Disease
    Mayte Suárez‐Fariñas, Minami A. Tokuyama, Gabrielle Wei, Ruiqi Huang, Alexandra E. Livanos, Divya Jha, Anaïs Levescot, Haritz Irizar, Roman Kosoy, Sascha Cording et al. · 2020 · Gastroenterology
  93. Pathophysiological characteristics and therapeutic approaches for pulmonary injury and cardiovascular complications of coronavirus disease 2019
    Yong‐Jian Geng, Zhi-Yao Wei, Hai‐Yan Qian, Ji Huang, Robert F. Lodato, Richard J. Castriotta · 2020 · Cardiovascular Pathology
  94. Cerebral ischemic and hemorrhagic complications of coronavirus disease 2019
    Ahmad Sweid, Batoul Hammoud, Kimon Bekelis, Symeon Missios, Stavropoula I. Tjoumakaris, Michael Reid Gooch, Nabeel A. Herial, Hekmat K. Zarzour, Victor M. Romo, Maureen DePrince et al. · 2020 · International Journal of Stroke
  95. Expression profiling meta-analysis of ACE2 and TMPRSS2, the putative anti-inflammatory receptor and priming protease of SARS-CoV-2 in human cells, and identification of putative modulators
    Eirini Gkogkou, Grigoris Barnasas, Konstantinos N. Vougas, Ioannis P. Trougakos · 2020 · Redox Biology
  96. ACE2 (Angiotensin-Converting Enzyme 2), COVID-19, and ACE Inhibitor and Ang II (Angiotensin II) Receptor Blocker Use During the Pandemic
    Andrew Michael South, Tammy McLoughlin Brady, Joseph T. Flynn · 2020 · Hypertension
  97. Combating Oxidative Stress and Inflammation in COVID‐19 by Molecular Hydrogen Therapy: Mechanisms and Perspectives
    Duried Alwazeer, Franky Fuh-Ching Liu, Xiao Yu Wu, Tyler W. LeBaron · 2021 · Oxidative Medicine and Cellular Longevity
  98. Innate Immune Signaling and Proteolytic Pathways in the Resolution or Exacerbation of SARS-CoV-2 in Covid-19: Key Therapeutic Targets?
    Jean‐Michel Sallenave, Loïc Guillot · 2020 · Frontiers in Immunology
  99. Blood pressure control and adverse outcomes of COVID-19 infection in patients with concomitant hypertension in Wuhan, China
    Jinjun Ran, Ying Song, Zian Zhuang, Lefei Han, Shi Zhao, Peihua Cao, Yan Geng, Lin Xu, Jing Qin, Daihai He et al. · 2020 · Hypertension Research
  100. Epidemiology and pathobiology of SARS-CoV-2 (COVID-19) in comparison with SARS, MERS: An updated overview of current knowledge and future perspectives
    Balasubramanian Ganesh, Thangarasu Rajakumar, Malathi Mathiyazhakan, Manikandan Natesan, Nagaraj Jaganathasamy, Santhakumar Aridoss, Elangovan Arumugam, Yashpal Singh Malik · 2021 · Clinical Epidemiology and Global Health